CClinicalTrials.gg
CompletedNCT03416296Updated Sep 16, 2021

Role of Ultrasound in Diagnosis of Placenta Previa and MAP

An observational study in Morbidly Adherent Placenta, sponsored by Aljazeera Hospital. Completed at 1 site in Egypt. Open to female participants aged 20 Years to 43 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-09-16.

Sponsored by Aljazeera Hospital · Observational

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
90
Ages
20 Years to 43 Years
Sex
Female
01

Study summary

Placenta accreta occurs when the placental implantation is abnormal. The marked rise in incidence has been assumed the increasing prevalence of cesarean delivery in recent years.

Read the detailed description

The most accepted theory is that abnormal placentation . The most important risk factor for placenta accreta is placenta previa after a prior cesarean delivery. The first clinical manifestation of placenta accreta is usually severe , life-threatening hemorrhage. The recommended intervention of suspected placenta accreta is planned preterm cesarean hysterectomy with the placenta left in situ.

02

Conditions studied

  • Morbidly Adherent Placenta
03

Who can participate

Ages eligible
20 Years to 43 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

pregnant females with previous cs will be subjected to US to assess placental location and MAP

Inclusion criteria

  • pregnant ladies with previous cesarean sections
  • GA above 30 weeks

Exclusion criteria

Exclusion Criteria:

  • Primigravida patients
  • GA below 30 weeks
04

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
90 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • normal placenta

    TA , TV ,TP us

  • placenta previa and MAP

    TA,TV.TP us

05

What researchers measure

Primary outcomes

  1. number of participants who will be diagnosed to have normal placenta or placenta previa or morbidly adherent placenta by US

    Time frame: within 6 weeks

06

Study locations

1 site
  • Algazeerah
    Giza, Egypt
07

Registry details

Key details

Study ID
NCT03416296
Lead sponsor
Aljazeera Hospital
Collaborators
Cairo University, National Research Centre, Egypt
Responsible party
Mahmoud Alalfy (Assistant Researcher , National Research centre and Specialist of Obstetrics and Gynecology in Aljazeerah hospital, Aljazeera Hospital) — Principal investigator
First posted
Jan 31, 2018
Start date
Mar 15, 2018
Primary completion
Jun 10, 2019
Completion
Dec 20, 2019
Last update
Sep 16, 2021

Study contacts

Mahmoud Alalfy
principal investigator · Algazeerah hospital -Location (Giza -Egypt ) and National Research centre egypt

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion